187 related articles for article (PubMed ID: 37597682)
1. An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel disease.
Zhang C; Zeng F; Fan Z; He Z; Tai L; Peng Q; Zhang Y; Chao Z; Jiang W; Jia L; Han L
Acta Biomater; 2023 Oct; 169():422-433. PubMed ID: 37597682
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy.
Wang X; Yan J; Wang L; Pan D; Xu Y; Wang F; Sheng J; Li X; Yang M
Theranostics; 2020; 10(23):10808-10822. PubMed ID: 32929381
[No Abstract] [Full Text] [Related]
3. Polyphenolic Nanoparticle-Modified Probiotics for Microenvironment Remodeling and Targeted Therapy of Inflammatory Bowel Disease.
Hu Q; Li J; Wang T; Xu X; Duan Y; Jin Y
ACS Nano; 2024 May; 18(20):12917-12932. PubMed ID: 38720520
[TBL] [Abstract][Full Text] [Related]
4. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease.
Bao M; Wang K; Li J; Li Y; Zhu H; Lu M; Zhang Y; Fan Q; Han L; Wang K; Wang D; Gao Y; Peng B; Ming Z; Liu W
Acta Biomater; 2023 Apr; 161():250-264. PubMed ID: 36863680
[TBL] [Abstract][Full Text] [Related]
5. Tannic acid and zinc ion coordination of nanase for the treatment of inflammatory bowel disease by promoting mucosal repair and removing reactive oxygen and nitrogen species.
Zhang C; Li Q; Xing J; Yang Y; Zhu M; Lin L; Yu Y; Cai X; Wang X
Acta Biomater; 2024 Mar; 177():347-360. PubMed ID: 38373525
[TBL] [Abstract][Full Text] [Related]
6. PPARGC1A affects inflammatory responses in photodynamic therapy (PDT)-treated inflammatory bowel disease (IBD).
Liu C; Jiang Y; Liu G; Guo Z; Jin Q; Long D; Zhou W; Qian K; Zhao H; Liu K
Biochem Pharmacol; 2022 Aug; 202():115119. PubMed ID: 35667414
[TBL] [Abstract][Full Text] [Related]
7. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
[TBL] [Abstract][Full Text] [Related]
8. Ultrathin Hafnium Disulfide Atomic Crystals with ROS-Scavenging and Colon-Targeting Capabilities for Inflammatory Bowel Disease Treatment.
Li R; Fan Y; Liu L; Ma H; Gong D; Miao Z; Wang H; Zha Z
ACS Nano; 2022 Sep; 16(9):15026-15041. PubMed ID: 36037406
[TBL] [Abstract][Full Text] [Related]
9. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease.
Zhang Q; Tao H; Lin Y; Hu Y; An H; Zhang D; Feng S; Hu H; Wang R; Li X; Zhang J
Biomaterials; 2016 Oct; 105():206-221. PubMed ID: 27525680
[TBL] [Abstract][Full Text] [Related]
10. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy.
Xu C; Chen S; Chen C; Ming Y; Du J; Mu J; Luo F; Huang D; Wang N; Lin Z; Weng Z
Int J Pharm; 2022 Jul; 623():121884. PubMed ID: 35661797
[TBL] [Abstract][Full Text] [Related]
11. Orally Administrated Inflamed Colon-Targeted Nanotherapeutics for Inflammatory Bowel Disease Treatment by Oxidative Stress Level Modulation in Colitis.
Min DK; Kim YE; Kim MK; Choi SW; Park N; Kim J
ACS Nano; 2023 Dec; 17(23):24404-24416. PubMed ID: 38039189
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease.
Chung CH; Jung W; Keum H; Kim TW; Jon S
ACS Nano; 2020 Jun; 14(6):6887-6896. PubMed ID: 32449857
[TBL] [Abstract][Full Text] [Related]
13. Orally Administered Silicon Hydrogen Nanomaterials as Target Therapy to Treat Intestinal Diseases.
Wei K; Gong F; Wu J; Tang W; Liao F; Han Z; Pei Z; Lei H; Wang L; Shao M; Liu Z; Cheng L
ACS Nano; 2023 Nov; 17(21):21539-21552. PubMed ID: 37843009
[TBL] [Abstract][Full Text] [Related]
14. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease.
Zhao J; Gao W; Cai X; Xu J; Zou D; Li Z; Hu B; Zheng Y
Theranostics; 2019; 9(10):2843-2855. PubMed ID: 31244927
[TBL] [Abstract][Full Text] [Related]
15. Self-assembly of affinity-controlled nanoparticles via host-guest interactions for drug delivery.
Xue F; Wang Y; Zhang Q; Han S; Zhang F; Jin T; Li C; Hu H; Zhang J
Nanoscale; 2018 Jul; 10(26):12364-12377. PubMed ID: 29682667
[TBL] [Abstract][Full Text] [Related]
16. Orally administered titanium carbide nanosheets as anti-inflammatory therapy for colitis.
Hou L; Gong F; Liu B; Yang X; Chen L; Li G; Gong Y; Liang C; Yang N; Shen X; Liu Z; Cheng L
Theranostics; 2022; 12(8):3834-3846. PubMed ID: 35664066
[No Abstract] [Full Text] [Related]
17. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-targeting polyamine nanomedicines for the treatment of ulcerative colitis.
Nishiguchi A; Taguchi T
J Mater Chem B; 2023 May; 11(18):4005-4013. PubMed ID: 37039159
[TBL] [Abstract][Full Text] [Related]
19. An Engineered Butyrate-Derived Polymer Nanoplatform as a Mucosa-Healing Enhancer Potentiates the Therapeutic Effect of Magnolol in Inflammatory Bowel Disease.
Fan X; Zhang Z; Gao W; Pan Q; Luo K; He B; Pu Y
ACS Nano; 2024 Jan; 18(1):229-244. PubMed ID: 38112525
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease.
Gowd V; Kanika ; Jori C; Chaudhary AA; Rudayni HA; Rashid S; Khan R
J Nutr Biochem; 2022 Nov; 109():109101. PubMed ID: 35777588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
